The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase III study of regorafenib versus placebo as maintenance therapy in RAS wild type metastatic colorectal cancer (RAVELLO trial).
 
Erika Martinelli
No Relationships to Disclose
 
Teresa Troiani
No Relationships to Disclose
 
Filippo Venturini
No Relationships to Disclose
 
Andres Cervantes
No Relationships to Disclose
 
Jean Yves Douillard
No Relationships to Disclose
 
Alfredo Falcone
No Relationships to Disclose
 
Gunnar Folprecht
Honoraria - Bayer; Lilly/ImClone; Merck KGaA
Consulting or Advisory Role - Bristol-Myers Squibb; Lilly/ImClone; Merck KGaA; Roche/Genentech
Research Funding - Merck KGaA
 
Claus-Henning Köhne
No Relationships to Disclose
 
Julien Taïeb
No Relationships to Disclose
 
Josep Tabernero
Consulting or Advisory Role - Amgen; Celgene; Chugai Pharma; ImClone Systems; Lilly; Merck KGaA; Millennium; Novartis; Roche/Genentech; Sanofi; Taiho Pharmaceutical
 
Claudia Cardone
No Relationships to Disclose
 
Vincenzo Sforza
No Relationships to Disclose
 
Giulia Martini
No Relationships to Disclose
 
Stefania Napolitano
No Relationships to Disclose
 
Annalisa Capuano
No Relationships to Disclose
 
Fabiana Auricchio
No Relationships to Disclose
 
Fortunato Ciardiello
No Relationships to Disclose